Education
About Us
Working with TipRanks
Follow Us
Personalis (PSNL)
:PSNL
PSNL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $7.20
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.02M
Market Cap
$274.64M
Enterprise Value$280.58M
Total Cash (Recent Filing)-$22.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Apr 30, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding88,308,205
10 Day Avg. Volume814,074
30 Day Avg. Volume1,021,671
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.71
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.46
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$7.43Price Target Upside138.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Personalis News
PremiumCompany Announcements
Personalis’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Personalis Reports 2024 Growth and Strategic Partnerships
---
Bulls Say, Bears Say
Bulls Say
Medicare CoverageThe recently published breast cancer study highlights the benefit of an ultra-sensitive MRD test, with submission for Medicare coverage in breast cancer now complete.
Strategic InvestmentsPersonalis ended the quarter with approximately $185M in cash and equivalents, including a $50M strategic investment by Merck.
Bears Say
Lowered Price TargetThe 12-month price target is lowered to $8.00 per share from the previous target of $11.00.
Revenue DeclineThe year-over-year revenue decrease was driven by lower Natera and VA MVP volumes.
---
Ownership Overview
21.83% Insiders
3.84% Mutual Funds
43.76% Other Institutional Investors
18.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $274.64M.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Apr 30, 2025 which is in 23 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on Feb 27, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.053.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.25.
How many shares outstanding does Personalis have?
Personalis has 88,308,205 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went down -2.358%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
---
Personalis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.43 (138.91% Upside)
$7.43 (138.91% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 330.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
122.14%
12-Months-Change
Fundamentals
Return on Equity
-48.91%
Trailing 12-Months
Asset Growth
20.07%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
---
PSNL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call detailed positive developments such as significant revenue growth in biopharma, strategic partnerships, and progress in clinical test volumes and reimbursement submissions. However, it also noted challenges like a decrease in quarterly revenue, lower gross margin expectations for 2025, and an expected decline in revenue from Natera. The sentiment is balanced, with significant achievements tempered by notable challenges.Read More>---
PSNL Stock 12 Month Forecast
Average Price Target
$7.43
▲(138.91% Upside)
Technical Analysis
Exact Sciences
―
Illumina
―
Rocket Pharmaceuticals
―
Fulgent Genetics
―
Guardant Health
―
Best Analysts Covering PSNL
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
+46.28%
reiterated a buy rating last month
Copying Michael Matson's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +46.28% per trade.
---